This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
This piece evaluates performance in retirement for Sp 500 vs Multi Asset approaches, outlining where each may excel under different conditions.
26,383 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Deribit and SignalPlus unveil The Island, a 35-day crypto trading contest with a prize pool of up to $600,000 USDC. T...
Meta’s legal exposure has surged to roughly $1.4 trillion ahead of a high-stakes August 2026 trial, testing how inves...
Analysts point to a stronger data center drive and autos growth as Qualcomm edges toward a new rally. With a $258 tar...
Jeff Bezos-led Blue Origin plans a $10 billion external round at a $130 billion valuation, a move that reframes priva...
When a top executive sells a large block of stock, investors want to know whether it signals trouble or simply person...
More than 60 analysts now rate the stock Buy as investors await the upcoming earnings release and assess cloud, adver...
An executive chair's sizable stock sale draws attention. This piece explains what the numbers mean, how to read insid...
As mega-cap tech pours capital into AI, investors seek signs of durable returns. This piece analyzes which firms stan...
Ethereum and Solana are trading well off their peaks as upgrades loom. The market is debating which will hit a new AT...
Delta leads in profitability amid a volatile fuel backdrop, while JetBlue shows resilience with a tighter balance she...
Two biotech powerhouses take very different routes: Moderna builds medicines with mRNA, while Recursion uses machine ...